Introduction {#s1}
============

There are 18.1 million new cancer cases and 9.6 million cancer deaths every year, as estimated by WHO ([@B5]). Platinum is the most widely used antitumor drug with a long history of drug development, including the first-generation cisplatin, second-generation carboplatin and nedaplatin, third-generation oxaliplatin and fourth-generation lobaplatin. Although more and more alternative strategies, such as derived nanoparticles, have been produced and implemented ([@B9]), platinum-based drugs still play a dominant role in clinical therapy, including basic, combination therapy and even radiotherapy ([@B15]). It has been reported that platinum antitumor drugs can cause adverse reactions related to neuro-, nephritic, hematic and immune toxicity ([@B26]; [@B6]), with immunotoxicity, including allergy, pruritus, diarrhea, nausea, and emesis, being the most common adverse reaction in our previous investigation, and may be due to the effects of immune system by killing cancer cells ([@B17]). Prior research has demonstrated inhibition of immune function by chemotherapeutic drugs, but some researchers have shown immune enhancement by platinum drugs ([@B29]; [@B2]; [@B8]). No matter whether inhibiting or enhancing the immune system, most of the research only focuses on the adverse reactions from one kind of platinum drug, but not the common toxicity from platinum drugs in general, and never consider whether the adverse reactions are due to platinum accumulation. Moreover, some patients display a poorer therapeutic effect after several courses of chemotherapy with the same dosage of platinum drugs, which also may relate to platinum accumulation. Reports indicate that the platinum level is 100--1,000 times higher in cancer patients 20 years after platinum chemotherapy than people without platinum therapy ([@B7]), and type I allergic reactions mediated by IgE in workers may be caused by platinum intake through breathing ([@B16]). Therefore, we believe that the adverse reactions related to platinum drugs may be due to accumulation of elemental platinum, especially for patients undergoing more courses of therapy, even though the original drug had been completely metabolized. There have been few studies on immune interference or its mechanisms by platinum, although studies of other heavy metals, such as lead and mercury, have appeared. For instance, lead can reduce the CD4^+^ subsets of T cells and the CD4/CD8 ratio, and influence expression of cytokines by Th1, Th2, and T cells. Chronic lead nitrate exposure results in decreased rat erythrocytes, hemoglobin, lymphocytes, and monocytes, and mercury exposure results in release of ROS, which inhibits IL-2-dependent signal transduction and reduces proliferation and survival of T cells ([@B3]; [@B19]; [@B22]; [@B14]). Concerning erythrocytes mediating immune regulation, the concentration of blood lead negatively correlates with CD44 and CD58 adhesion molecule expression ([@B13]). Lead also has been reported to correlate with anemia ([@B12]), and it has been suggested that cisplatin, as well as other metals, may participate in oxidative stress, causing inflammation by cytokines ([@B17]), and finally interfering with immune function. As another heavy metal, platinum could perhaps also interfere with the immune system. We therefore explored the change of related hemocyte levels, as well as adverse reactions, in response to platinum accumulation after complete metabolism of the drug, to establish a mechanism of platinum immune response toxicity and offer insight on immunological mechanisms of platinum toxicity.

Methods and Materials {#s2}
=====================

Sample Collection {#s2_1}
-----------------

Cases of cancer patients with platinum drug chemotherapy were randomly recruited after diagnosis by a doctor according to the NCCN (National Comprehensive Cancer Network) in the Cancer Hospital of Shantou University Medical College. All patients were eligible for enrollment and exclusion conditions before medication shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Recruitment criteria.

  Enrollment criteria                                   Exclusion criteria
  ----------------------------------------------------- -----------------------------------------------------------
  Required platinum drug chemotherapy after diagnosis   Metallurgical industry employee Metastatic tumor
  Estimated lifetime \> 6 months                        Pregnant or lactating
  Hematological index within the normal range           Prior medication involving platinum or other chemotherapy
  Provided informed consent to this research            Accompanied by inflammation

Oxaliplatin has a half-life of 46 h, whereas cisplatin has 72 h. In theory, both drugs should be cleared completely after 5.5 times the half-life, which would be 10.5 days for oxaliplatin and 16.5 days for cisplatin. The time interval of chemotherapy was set at three weeks between rounds, according to drug elimination and the clinical requirements of the NCCN. We chose the day before the next round of chemotherapy as the specified time point for blood sampling and collected samples at five time points for the corresponding courses. Finally, we obtained 187 cases after eliminating invalid samples, 89 for oxaliplatin and 97 for cisplatin, from January to December in 2018. The dosage of oxaliplatin and cisplatin was set by the oncologist according to body surface area and the NCCN, as shown in [**Table 3**](#T3){ref-type="table"}.

Whole blood was extracted by elbow venous in all cases. A total of 1 ml was extracted in a heparin anticoagulant tube for hematological index analysis, and 3 ml was centrifuged (1,200 g, 3 min) to obtain serum for platinum measurement. Adverse reactions were simultaneously recorded. All protocols in this investigation were approved by the Human Ethics Committee of the Cancer Hospital of Shantou University Medical College, China (2015030907). All patients signed informed consent.

Hematological Index Analysis {#s2_2}
----------------------------

Hematological indices were measured with an automatic blood analyzer (Beckman-LH780, USA) immediately after sample collection by the methods on impedance measurement and cyanated methemoglobin colorimetric procedure.

Measurement of Serum Platinum {#s2_3}
-----------------------------

A total of 100 μl serum sample and 900 μl 0.5% nitric acid (65%, guarantee) were mixed by vortexing and quantified by graphite furnace atomic absorption spectrophotometry (Jena ZEEnit 650, Germany). Parameters for the AAS-650 were a 265.9 nm wavelength, 0.2 nm slit width, 8 mA Pt-lamp current and the temperature program was shown in [**Table 2**](#T2){ref-type="table"}. The limit of detection (LOD) was 31.16 μg/L and accuracy of this method was verified by recoveries between 91.73 and 98.31% from spiked serum samples.

###### 

Temperature program for the AAS-650.

                Temperature/°C   Heating rate/°C/s   Retention time/s
  ------------- ---------------- ------------------- ------------------
  Drying 1      90               5                   20
  Drying 2      105              3                   20
  Drying 3      110              2                   30
  Pyrolysis     1150             250                 20
  Atomization   2700             700                 5
  Clean out     2800             500                 4

Adverse Reaction Record at Each Corresponding Time Point {#s2_4}
--------------------------------------------------------

Adverse reactions were assessed and recorded by a clinical doctor at each time point, based on The Common Terminology Criteria for Adverse Events (CTCAE, 5.0). We recorded the adverse reactions, including diarrhea, nausea, emesis and allergy, and classified them into five grades (from 0-no symptoms to 4-severe life-threatening).

Statistical Analysis {#s2_5}
--------------------

Nonparametric analysis was performed, using the Kolmogorov-Smirnov test, for frequency distribution; data with skewed distributions was represented by median and 25^th^--75^th^ percentile, the comparison of rates was performed by the chi-square test, skewed data was compared by non-parametric testing (Mann Whitney U test), and correlation analysis was performed by Spearman rank correlation analysis. The concentration-response relationship was analyzed by binary logistic regression. All analyses were performed with SPSS 22.0 (IBM Corporation, USA) and GraphPad Prism 7.0 (GraphPad, CA) software. A *P*\<0.05 was considered as statistically significant in all analyses.

Results {#s3}
=======

General Characteristics of the Study Population {#s3_1}
-----------------------------------------------

In this study, there were 89 patients who were treated with oxaliplatin and 97 with cisplatin, with a higher proportion of female patients and lower average age in the cisplatin-treated group. No significant differences were found in height, weight and BMI between the patients in both groups (*P*\>0.05, [**Table 3**](#T3){ref-type="table"}). Oxaliplatin-treated patients had mostly colon, rectum, and gastroesophageal junction cancers, whereas cisplatin-treated patients had lung, nasopharyngeal and cervix cancers ([**Figure 1**](#f1){ref-type="fig"}).

###### 

General characteristics of the study population.

                           Oxaliplatin (n = 89)   Cisplatin (n = 97)   *P*
  ------------------------ ---------------------- -------------------- -------
  Gender (males/females)   64/25                  51/46                0.007
  Height (mean ± SD, cm)   164.9 ± 5.9            163.5 ± 6.2          0.103
  Weight (mean ± SD, kg)   55.8 ± 6.5             54.2 ± 7.0           0.107
  BMI (mean ± SD, kg/m2)   20.4 ± 1.5             20.2 ± 1.5           0.234
  Age (mean ± SD, years)   59.4 ± 10.7            55.8 ± 9.7           0.017
  Surgery \[n (%)\]                                                    0.000
   1=No                    37 (41.6)              66(68.0)             
   2=Yes                   52 (58.4)              31(32.0)             
  Dose (mg/m\^2)           85                     65                   /

![Distribution of cancer types in **(A)** oxaliplatin- and **(B)** cisplatin-treated patients.](fphar-11-01166-g001){#f1}

Platinum Accumulation {#s3_2}
---------------------

### Serum Platinum of Patients With Different Drugs {#s3_2_1}

The serum platinum concentration of the two groups showed a non-normal distribution and was analyzed by the median. The concentration of platinum displayed a high degree of dispersion with a median of 294.8 (205.6, 440.3) μg/L in all subjects, with the cisplatin group being significantly higher than oxaliplatin, 429.3 (340.3, 539.5) vs. 211.7 (160.9, 275.5) μg/L, (*P*\<0.01, [**Figure 2**](#f2){ref-type="fig"}).

![Median serum platinum concentration in each patient group (μg/L). \*\*: *P*\<0.01.](fphar-11-01166-g002){#f2}

### Serum Platinum at Different Time Points {#s3_2_2}

After analysis of the platinum concentration at each of the five time points, we found significantly different concentrations by the Kolmogorov-Smirnov test between each time point, with peak values obtained at the third point for both oxaliplatin and cisplatin treatments (*P*\<0.05, [**Table 4**](#T4){ref-type="table"}).

###### 

Median serum platinum concentration at each time point.

                1st point   2nd point   3rd point   4th point   5th point   *P* for K-S test
  ------------- ----------- ----------- ----------- ----------- ----------- ------------------
  Oxaliplatin   164.1       216.3       251.4       216.1       201.6       0.049
  Cisplatin     305.8       476.9       514.8       439.0       417.9       0.001

### Serum Platinum in Different Genders {#s3_2_3}

We grouped the serum platinum data by gender and found the median level was significantly higher in females than males, with median values being 383.9 (240.0, 496.7) vs. 266.5 (181.9,400.8) μg/L (*P \<*0.05) for females and males, respectively.

Correlations Between Serum Platinum and Hematological Indices {#s3_3}
-------------------------------------------------------------

### Hematological Indices in Two Groups {#s3_3_1}

We divided the cases into low- and high-platinum groups by the mean of the natural logarithm of platinum concentration, compared the hematological index in the two groups ([**Figure 3**](#f3){ref-type="fig"}). The count of leucocyte was lower in the low platinum group than that in the high platinum group (*P*\<0.05). On the contrary, erythrocyte count and hemoglobin took higher levels in the low platinum group (*P*\<0.01). There is no significant difference on platelet between the two groups.

![Hematological indices in two groups. \*\*: *P*\<0.01; \*: *P*\<0.05.](fphar-11-01166-g003){#f3}

### Correlations Between Serum Platinum and Hematological Indices {#s3_3_2}

Spearman correlation analysis showed a positive correlation between platinum level and leukocyte and platelet counts, but negative correlations between platinum level and erythrocyte counts and hemoglobin (*P*\<0.05, [**Figure 4**](#f4){ref-type="fig"}). The current definition of anemia is hemoglobin \<120 g/L in adult males, or hemoglobin \<110 g/L in adult females (non-pregnancy). In this study, the hemoglobin mean of male and female patients was 119.1 ± 16.4 vs.112.4 ± 12.0 g/L, respectively, with the incidence of anemia being 51.3 vs. 39.4% (no significant difference between male and female groups, *P*\>0.05). To determine the correlation between anemia and platinum, a binary logistic regression model was used with occurrence of anemia as a dependent variable (1=no, 2=yes) and platinum as an independent variable. The results showed that the risk of anemia increased 0.002-fold for every unit (μg/L) increase of serum platinum concentration (*P*\<0.05, [**Table 5**](#T5){ref-type="table"}).

![Correlation between serum platinum and hematological indices.\*\**P*\<0.01; \**P*\<0.05.](fphar-11-01166-g004){#f4}

###### 

Relationship between anemia and platinum.

           Platinum level                 
  -------- ---------------- ------------- -------
  Anemia   1.002            1.001,1.004   0.009

Correlations Between Adverse Reactions and Serum Platinum {#s3_4}
---------------------------------------------------------

We recorded the adverse reactions related to immune toxicity of tumor patients and observed almost no serious events ([**Table 6**](#T6){ref-type="table"}). However, the chi-square test showed that there was a significant difference between males and females, with the latter displaying a higher incidence of more serious cases (50.7% vs.19.1%, *χ^2^* = 20.393, *p*=0.000).

###### 

Cases of adverse reactions related to immune toxicity.

  Adverse events   Nausea   Emesis   Diarrhea   Allergy   Amount                    
  ---------------- -------- -------- ---------- --------- -------- --- --- --- ---- ----
  1                6        10       3          4         2        2   3   3   14   19
  2                4        8        1          3         1        2   2   3   8    16
  3                0        0        0          0         0        1   0   0   0    1
  Amount           10       18       4          7         3        5   5   6   22   36

Spearman correlation analysis showed that serum platinum was positively correlated with the incidence and degree of adverse reactions (*r~s~*=0.466, *P*\<0.01; *r~s~*=0.490, *P*\<0.01). In order to further analyze the concentration-response relationship between serum platinum and adverse reactions, a binary logistic regression model was used with the occurrence of adverse reaction as a dependent variable (1=no, 2=yes), serum platinum concentration as an independent variable, and following adjustment for gender and age. The results showed that the risk of adverse reactions was increased by 0.007 times for every unit (μg/L) increase of serum platinum concentration, after adjustment with gender, age, surgery, cancer types (*P \<*0.05, [**Table 7**](#T7){ref-type="table"}).

###### 

Relationship between adverse reactions and platinum.

  Adverse reaction   Platinum level                  
  ------------------ ---------------- -------------- -------
  Model 1            1.007            1.005, 1.009   0.000
  Model 2            1.007            1.004, 1.009   0.000

Model 1: unadjuted;

Model 2: adjusted with gender, age, surgery, cancer type.

Discussion {#s4}
==========

Platinum Accumulation {#s4_1}
---------------------

In this study, we found accumulation of platinum in cancer patients after rational interval of chemotherapy and was higher in cisplatin- than oxaliplatin-treated patients (429.3 vs. 211.7 μg/L). It is the first time to compare platinum accumulation of these two drugs, although a study on cisplatin has been reported indicating its continued presence 20 years after therapy ([@B16]). The original levels of platinum in the two groups were consistent, based on calculations of drug structure and dosage. Differences in platinum accumulation may be due to different drug structures, which would have different binding rates of metabolites with glutathione, cysteine, and ABCC protein ([@B4]; [@B24]). Hence, we attribute the difference of platinum accumulation, between cisplatin and oxaliplatin, to molecular structural differences. Moreover, we found large individual and gender differences in platinum levels, perhaps related to polymorphisms of the *GSTP1* and *XRCC1* genes, and drug metabolic diversity *in vivo* ([@B21]; [@B11]). Our finding is consistent with prior research showing that the elimination time for platinum is more than 25 times that for the intact platinum-based drug in the rat ([@B20]). In addition, there was an increasing trend over the first three time points, which reflected the platinum accumulation. A decreasing trend was observed from the fourth time point, which we suspect was due to greater clearance of the original drug because of the development of resistance to platinum drugs in patients. Most reports have attributed the resistance mechanism to gene mutation or methylation ([@B1]; [@B27]), autophagy induction by cisplatin ([@B10]), and acquisition of resistance to oxaliplatin accompanied by cross-resistance to another metal such as copper ([@B18]). As a result, we consider the trend of platinum distribution as a drug resistance phenomenon caused by platinum accumulation.

Associations Between Immune Toxicity and Platinum Accumulation {#s4_2}
--------------------------------------------------------------

Adverse reactions, such as diarrhea and myelosuppression, in chemotherapy of some platinum drugs (for example: cisplatin, oxaliplatin, or carboplatin) result from toxicity to rapidly dividing cells ([@B2]), but more and more data has shown interference of immune system function by platinum drugs. For instance, oxaliplatin and cisplatin can increase production of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), *in vivo* and stimulate the immune response ([@B17]; [@B23]).

Heavy metals can interfere with inflammation mediated by leukocytes and their subsets. For instance, cadmium affects the telomere length of leukocytes and immune regulation ([@B30]), lead and cadmium may change the counts of leukocytes and their subsets ([@B28]). In our research, there were almost no serious adverse reactions of patients, and the more frequent and serious cases were exhibited by the female patients. We also found that residual serum platinum was positively correlated with leukocyte and thrombocyte counts, as well as the incidence of adverse reactions, such as diarrhea, nausea, emesis, and allergy after a period sufficient for drug elimination. Regression analysis further showed the increasing risk of platinum toxicity on immune inflammation mediated by leukocytes.

On the other hand, serum platinum may result in anemia, as shown by the negative correlation with erythrocytes and hemoglobin, and regression analysis showed the risk of increasing platinum on anemia, which is similar to other divalent metals due to a competitive inhibition of iron ion ([@B12]; [@B25]). Erythrocyte counts are traditionally considered an index of anemia, but more and more research has pointed out its role in immunoregulation. Blood lead has been reported to negatively correlate with adhesion molecules (CD44 and CD58) of erythrocytes ([@B13]), which hints toward a correlation between platinum accumulation, similar to lead, and immune toxicity mediated by erythrocytes.

In all, we conducted a study on the relationship between platinum accumulation, immunocytes and subsequent adverse reactions. The results show significant correlations between all three, as well as differing toxicities in different genders. All results demonstrate that drug-induced platinum accumulation may stimulate the immune system, as is the case with other heavy metals, and further lead to immune toxicity. Influences on adverse reactions and anemia risk mediated by platinum accumulation suggests that quelation therapy and nourishment to enhance immune function for patients should be considered. The mechanism of platinum resistance is still not clear, but our study suggests that it may due to the platinum accumulation resulting from subsequent rounds of chemotherapy. More and intensive study on the mechanism of immune toxicity caused by platinum accumulation should be carried out in the future.
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